Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Diabetes drug may increase cardiovascular risk

  • Comment

Data has suggested an increased risk of cardiovascular problems for diabetes patients treated with the drug rosiglitazone (Avandia, Avandamet), the Medicines and Healthcare products Regulatory Agency has warned.

It said a Europe-wide review of the drug was under way, but until the results were known the MHRA advised healthcare professionals to closely observe contraindications and monitoring requirements for rosiglitazone, and to use alternatives where possible.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs